Related references
Note: Only part of the references are listed.Comparative gene expression profiling of human metallothionein-3 up-regulation in neuroblastoma cells and its impact on susceptibility to cisplatin
Miguel Angel Merlos Rodrigo et al.
ONCOTARGET (2018)
A physiologically relevant 3D collagen-based scaffold-neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models
C. Curtin et al.
ACTA BIOMATERIALIA (2018)
Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion
Mario Mauthe et al.
AUTOPHAGY (2018)
Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
Belinda van Zyl et al.
ENDOCRINE-RELATED CANCER (2018)
Vandetanib inhibits cisplatin-resistant neuroblastoma tumor growth and invasion
Changchun Li et al.
ONCOLOGY REPORTS (2018)
An insight into the complex roles of metallothioneins in malignant diseases with emphasis on (sub)isoforms/isoforms and epigenetics phenomena
Sona Krizkova et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Hydrogen sulfide ameliorates zinc-induced cell death in neuroblastoma SH-SY5Y cells
Megumi Shimoji et al.
FREE RADICAL RESEARCH (2017)
YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma
Chao Yang et al.
ONCOTARGET (2017)
Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma
Laura Annovazzi et al.
CANCERS (2017)
Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells
Magdalena Circu et al.
PLOS ONE (2017)
Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Jan Hrabeta et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2016)
Platinum-based drugs: past, present and future
Shahana Dilruba et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment
Sarah Andrea Roth et al.
CANCER LETTERS (2016)
Breaking the DNA damage response to improve cervical cancer treatment
Hylke W. Wieringa et al.
CANCER TREATMENT REVIEWS (2016)
Leaving the lysosome behind: novel developments in autophagy inhibition
Abigail R. Solitro et al.
FUTURE MEDICINAL CHEMISTRY (2016)
HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma
Omid Tavana et al.
NATURE MEDICINE (2016)
Combined cisplatin and aurora inhibitor treatment increase neuroblastoma cell death but surviving cells overproduce BDNF
Alessio Polacchini et al.
BIOLOGY OPEN (2016)
Serum metallothionein in patients with testicular cancer
Blanka Tariba et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro (vol 364, pg 142, 2015)
Olga Piskareva et al.
CANCER LETTERS (2015)
Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function
Liwei Ma et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Metallothionein 3 Expression in Normal Skin and Malignant Skin Lesions
Bartosz Pula et al.
PATHOLOGY & ONCOLOGY RESEARCH (2015)
Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma
Hung C. Tran et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2015)
Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death
Ana M. Villamil Giraldo et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Cisplatin in cancer therapy: Molecular mechanisms of action
Shaloam Dasari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Ototoxicity in Children With High-Risk Neuroblastoma: Prevalence, Risk Factors, and Concordance of Grading Scales-A Report From the Children's Oncology Group
Wendy Landier et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Systems biology of cisplatin resistance: past, present and future
L. Galluzzi et al.
CELL DEATH & DISEASE (2014)
Carboplatin: molecular mechanisms of action associated with chemoresistance
Graziele Fonseca de Sousa et al.
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model
Yiwu Yan et al.
CELL RESEARCH (2013)
Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Jana Drbohlavova et al.
CURRENT DRUG METABOLISM (2013)
Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers
Pavel Prochazka et al.
ONCOLOGY REPORTS (2013)
Metallothioneins and zinc in cancer diagnosis and therapy
Sona Krizkova et al.
DRUG METABOLISM REVIEWS (2012)
Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification
Linda J. Valentijn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes
Ding-Wu Shen et al.
PHARMACOLOGICAL REVIEWS (2012)
Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma
J. Gumulec et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Reciprocal Potentiation of the Antitumoral Activities of FK866, an Inhibitor of Nicotinamide Phosphoribosyltransferase, and Etoposide or Cisplatin in Neuroblastoma Cells
Cristina Travelli et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
New Insights into Neuroblastoma Cisplatin Resistance: A Comparative Proteomic and Meta-Mining Investigation
Simona D'Aguanno et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Lysosomotropic agents as HCV entry inhibitors
Usman A. Ashfaq et al.
VIROLOGY JOURNAL (2011)
Metallothionein-3 Regulates Lysosomal Function in Cultured Astrocytes Under Both Normal and Oxidative Conditions
Sook-Jeong Lee et al.
GLIA (2010)
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma
Alexander Swarbrick et al.
NATURE MEDICINE (2010)
Lysosomal membrane permeabilization in cell death
P. Boya et al.
ONCOGENE (2008)
Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Paul Wright
Recent Patents on Anti-Cancer Drug Discovery (2008)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
Mechanisms of resistance to cisplatin and carboplatin
David J. Stewart
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma
Brian H. Kushner et al.
CANCER (2006)
Metallothioneins and resistance to cisplatin and radiation in prostate cancer
David J. Smith et al.
UROLOGY (2006)
Drug resistance in ovarian cancer: The emerging importance of gene transcription and spatio-temporal regulation of resistance
A Richardson et al.
DRUG RESISTANCE UPDATES (2005)
Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles (vol 49, pg 438, 2002)
I Iwasaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Particular aspects of platinum compounds used at present in cancer treatment
B Desoize et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Share Paper
